Treatments | EGFR Lung Cancer Resisters

22 November 2018

PATIENTS LAUNCH NEW STUDY TO SHED LIGHT ON EGFR-POSITIVE LUNG CANCERS

PATIENTS LAUNCH NEW STUDY TO SHED LIGHT ON EGFR-POSITIVE LUNG CANCERS

laurabbook@gmail.com2018-11-22T13:19:38+00:00

Scientists, physicians and patients collaborate to improve treatment for rare cancer SAN CARLOS, CA (November 14, 2018) — The Addario Lung Cancer

PATIENTS LAUNCH NEW STUDY TO SHED LIGHT ON EGFR-POSITIVE LUNG CANCERSlaurabbook@gmail.com2018-11-22T13:19:38+00:00

22 November 2018

Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors

Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors

laurabbook@gmail.com2018-11-22T12:55:52+00:00

*NATURE COMMUNICATIONS | (2018) 9:4655 | DOI: 10.1038/s41467-018-07078-0 | www.nature.com/naturecommunications * The emergence of acquired resistance against targeted drugs remains

Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitorslaurabbook@gmail.com2018-11-22T12:55:52+00:00

22 November 2018

J&J buys novel lung cancer drug from South Korea’s Yuhan

J&J buys novel lung cancer drug from South Korea’s Yuhan

laurabbook@gmail.com2018-11-22T12:43:11+00:00

*November 7, 2018* Janssen Biotech has bought Yuhan’s Lazertinib, a novel clinical-stage therapeutic candidate for the treatment of patients with

J&J buys novel lung cancer drug from South Korea’s Yuhanlaurabbook@gmail.com2018-11-22T12:43:11+00:00